Clean Biologics specializes in viral and biological safety of biopharmaceuticals, GMP-grade production and storage of starting materials and GMP-grade manufacturing of cell banks and virus seed stock as drug substances for clinical trials. The company’s contract development and manufacturing activities in viral vectors and therapeutic proteins are branded under the names Naobios and Biodextris following their acquisition in 2019 and 2021, significantly reinforcing Clean Biologics services offering in the biopharmaceutical development value chain.